Header image
![](/sites/default/files/styles/page_header_image/public/2023-07/foto_zahlavi_research_1.jpg?itok=p7pBtlZR)
Treatment of Allergic Asthma With Fenretinide Formulation (LAU-7b) Downregulates ORMDL Sphingolipid Biosynthesis Regulator 3 ( Ormdl3) Expression and Normalizes Ceramide Imbalance
Treatment of Allergic Asthma With Fenretinide Formulation (LAU-7b) Downregulates ORMDL Sphingolipid Biosynthesis Regulator 3 ( Ormdl3) Expression and Normalizes Ceramide Imbalance.
The Journal of Pharmacology and Experimental Therapeutics.
2020,
373(3),
476-487,
ISSN: 0022-3565,
PMID: 32273303,